Labiriad (Aciclovir)

Aciclovir is converted inside infected cells to aciclovir triphosphate, which mimics the natural building blocks of DNA. This active form binds to viral DNA polymerase, blocking the addition of nucleotides and causing premature termination of viral DNA synthesis, thereby inhibiting virus replication.

The specific dosage and frequency of Labiriad are determined by the prescribing healthcare professional based on the severity of the infection, patient age, and clinical response. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Safety data for aciclovir in pregnancy and lactation are limited. The decision to use Labiriad during pregnancy or while breastfeeding should be made by a qualified healthcare provider after weighing potential benefits against possible risks to the mother and infant.

To request Labiriad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Labiriad’s topical aciclovir formulation offers localized delivery directly to oral lesions, which can provide faster symptom relief compared with systemic antivirals that require oral or intravenous administration. It is particularly useful for mild to moderate oral herpes infections where targeted therapy is preferred.

Store Labiriad at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme temperatures to maintain its stability and effectiveness.

Labiriad is applied directly to the affected gingival or oral area using the supplied applicator or a clean fingertip. The medication should be spread thinly over the lesion, following the prescriber’s instructions regarding frequency and duration of treatment.

Serious adverse reactions, though rare, can include severe allergic responses such as anaphylaxis, extensive ulceration of gingival tissue, systemic hypersensitivity with rash, and renal impairment in patients with pre‑existing kidney disease. Prompt medical attention is required if any of these occur.

Labiriad should be avoided in individuals with a known hypersensitivity to aciclovir or any component of the formulation. Patients with severe renal dysfunction should consult a healthcare professional before use, as dose adjustments may be necessary.